Abstract
Voltage-gated sodium channels (NaV) are well validated targets for treating pain based both on human genetics and clinical experience. Consequently, there is an extensive literature on sodium channels for the treatment of pain and a number of excellent and thorough reviews have recently appeared; a selection of these is provided. This review does not attempt to evaluate all aspects of the studies in this area, but rather will focuses on several key issues that are incompletely addressed in prior reviews or that represent very recent additions to the literature. Key questions that arise are: 1) How much channel block is required to observe efficacy against neuropathic or inflammatory pain? 2) How can one improve upon the therapeutic index of previously tested NaV blockers?
Keywords: Analgesia, NaV, pain, voltage-gated sodium channel, channel block, efficacy, neuropathic or inflammatory pain, therapeutic index, ANALGESIC ACTIVITY, inflammed tissue, PET ligands
Current Pharmaceutical Biotechnology
Title: Targeting Voltage-Gated Sodium Channels for Treating Neuropathic and Inflammatory Pain
Volume: 12 Issue: 10
Author(s): Charles J. Cohen
Affiliation:
Keywords: Analgesia, NaV, pain, voltage-gated sodium channel, channel block, efficacy, neuropathic or inflammatory pain, therapeutic index, ANALGESIC ACTIVITY, inflammed tissue, PET ligands
Abstract: Voltage-gated sodium channels (NaV) are well validated targets for treating pain based both on human genetics and clinical experience. Consequently, there is an extensive literature on sodium channels for the treatment of pain and a number of excellent and thorough reviews have recently appeared; a selection of these is provided. This review does not attempt to evaluate all aspects of the studies in this area, but rather will focuses on several key issues that are incompletely addressed in prior reviews or that represent very recent additions to the literature. Key questions that arise are: 1) How much channel block is required to observe efficacy against neuropathic or inflammatory pain? 2) How can one improve upon the therapeutic index of previously tested NaV blockers?
Export Options
About this article
Cite this article as:
J. Cohen Charles, Targeting Voltage-Gated Sodium Channels for Treating Neuropathic and Inflammatory Pain, Current Pharmaceutical Biotechnology 2011; 12 (10) . https://dx.doi.org/10.2174/138920111798357249
DOI https://dx.doi.org/10.2174/138920111798357249 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patent Selections:
Recent Patents on Biotechnology CXCR2 Receptor Antagonists: A Medicinal Chemistry Perspective
Current Topics in Medicinal Chemistry G Protein-Coupled Receptors: Target-Based In Silico Screening
Current Pharmaceutical Design Nitric Oxide Mimetic Molecules as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Adverse Systemic Reactions of Antihistamines: Highlights in Sedating Effects, Cardiotoxicity and Drug Interactions
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Renin-angiotensin System as a Target of Novel Anticancer Therapy
Current Pharmaceutical Design Antagonizing the Calcium-Sensing Receptor: Towards New Bone Anabolics?
Current Molecular Pharmacology The GNAS Locus: Quintessential Complex Gene Encoding Gsα, XLαs, and other Imprinted Transcripts
Current Genomics Demonstration of the Efficacy of Statins in Resolution of Plaque Inflammation by Serial FDG Imaging
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Combining “Omics” Strategies to Analyze the Biotechnological Potential of Complex Microbial Environments
Current Protein & Peptide Science Microvascular Thrombosis: An Exciting but Elusive Therapeutic Target in Reperfused Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Challenge and Therapeutic Studies Using Alpha-Methyl-para-Tyrosine (AMPT) in Neuropsychiatric Disorders: A Review
Central Nervous System Agents in Medicinal Chemistry Tobacco Smoke Exposure, Nicotine, and the Embryologic Origins of Asthma
Current Respiratory Medicine Reviews A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Approaches to Minimize Infection Risk in Blood Banking and Transfusion Practice
Infectious Disorders - Drug Targets Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile
Current Pharmaceutical Design Dry Eye Disease: Present Challenges in the Management and Future Trends
Current Pharmaceutical Design The Guanylyl Cyclase Inhibition by MB as Vasoplegic Circulatory Shock Therapeutical Target
Current Drug Targets